JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective raised by investment analysts at JPMorgan Chase & Co. from $900.00 to $950.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 28.01% from the company’s current price.

REGN has been the subject of several other research reports. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a report on Thursday, July 9th. HSBC upped their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research note on Tuesday, July 7th. Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Finally, Argus raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 target price on the stock in a research report on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $814.88.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $742.12 on Tuesday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The firm has a market cap of $76.41 billion, a PE ratio of 18.34, a P/E/G ratio of 1.41 and a beta of 0.16. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $859.34. The stock has a fifty day moving average price of $791.29 and a 200-day moving average price of $720.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the previous year, the business earned $12.81 EPS. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. Equities research analysts predict that Regeneron Pharmaceuticals will post 45.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the sale, the director owned 603 shares in the company, valued at $512,550. This represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the sale, the executive vice president owned 12,003 shares in the company, valued at approximately $10,291,252.17. This represents a 8.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,946 shares of company stock valued at $3,302,458 over the last quarter. 6.97% of the stock is currently owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. SHP Wealth Management purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $26,000. Western Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $26,000. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $29,000. Mowery & Schoenfeld Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $29,000. Finally, Trust Co. of Vermont purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $29,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts raised price targets: Truist Financial lifted its target from $772 to $780 and upgraded its view to buy, implying about 5.1% upside. JPMorgan also raised its target from $900 to $950 and maintained an overweight rating, representing roughly 28% potential upside. Regeneron Price Target Raised to $950
• Positive Sentiment: Sanofi alliance expands pipeline funding: Regeneron entered an expanded antibody collaboration with Sanofi that includes $1 billion upfront and as much as $7 billion in potential milestone payments. The agreement could support development of new immunology, oncology, and obesity treatments beyond the company’s current blockbusters. Expanded Sanofi Alliance and New Pipeline Data
• Positive Sentiment: New cancer data strengthen Libtayo’s growth prospects: Regeneron presented longer-term Phase 3 C-POST survival data for adjuvant Libtayo in high-risk cutaneous squamous cell carcinoma, along with Phase 2 neoadjuvant data and research into Factor XI inhibition for cancer-associated thrombosis. The results support efforts to expand Libtayo’s use and diversify the pipeline. Regeneron ESMO 2026 Data
• Neutral Sentiment: Analyst views remain mixed: Morgan Stanley raised its target from $758 to $779 but retained an equal weight rating. Coverage describing analysts as conflicted suggests that pipeline opportunities are being weighed against execution and commercial risks. Analysts Conflicted on Regeneron

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.